Compare Garmin Ltd. (GRMN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Garmin Ltd. trades at $287.86 (market cap $53.94B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.91 (market cap $977.37M). The key difference: Garmin Ltd. is far larger — about 55.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Garmin Ltd. pays a 1.5% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 84 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GRMN | MRVI | |
|---|---|---|
Market Cap | $53.94B | $977.37M |
Volume | 947,987 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $313.16 | $9.00 |
52-Week Low | $187.10 | $2.83 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $51.46B | $1.08B |
Dividend Yield | 1.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.41, up 3.62% today, with a bearish technical signal but strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily from 2022 to 2025, supported by robust profitability margins. Recent news highlights product innovations and industry awards, reinforcing its market position.
The outlook is mixed; strong earnings growth and a consensus price target of $323.20 suggest upside potential, but technical indicators signal near-term caution. Risks include competitive pressures and market volatility. Analyst sentiment is predominantly neutral, with 71.43% hold ratings, indicating a wait-and-see approach amid solid operational performance.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
